The money behind the milestones
Biotech headlines in late 2026 are mostly about trial readouts and regulatory filings. The financial question underneath them is simpler: who can pay for the next stage? The cleanest answer in our verified data is Incyte Corporation. Its net income was $597.6 million in fiscal 2023, fell to $32.6 million in fiscal 2024, then rose to $1,286.7 million in fiscal 2025.1 That is roughly 39 times the 2024 figure (our arithmetic). Earnings per share followed the same path: $2.65, then $0.15, then $6.41.1
Every figure in this section is canonical, meaning checked against the company's SEC filings. None of it is a press-release claim.
Where the profit came from
Operating income, which is profit from running the business before interest and tax, went from $620.5 million in 2023 to $61.4 million in 2024 and then to $1,514.9 million in 2025.1 Cost of revenue rose steadily over the same period: $255.0 million, $312.1 million, then $372.1 million.1 Costs of making and delivering product grew by about 46% from 2023 to 2025 (our arithmetic). Operating income grew far faster than that, so the 2025 jump came from higher revenue and not from cost-cutting. The dossier does not break down the revenue, so we cannot say which products drove it.
Cash generation tells the same story. Operating cash flow was $496.5 million in 2023, $335.3 million in 2024 and $1,413.5 million in 2025.1 The 2025 figure is more than four times the 2024 one. Incyte therefore did not just report a better profit. It collected the cash.
A balance sheet that moved the other way first
Cash tells a less tidy story. Incyte held $3,213.4 million at the end of fiscal 2023, but only $1,687.8 million at the end of fiscal 2024. The quarterly path in between dipped as low as $987.3 million in Q2 2024. Cash then rebuilt to $3,097.8 million at the end of fiscal 2025 and reached $3,461.1 million in Q1 2026.1 We have not been given the cause of the 2024 drop, so we will not guess at it. A reader can still see that cash at Incyte moves a lot from period to period, and that the year-end figures show only part of that.
For scale, Incyte spent $1,627.6 million on research and development in fiscal 2023, the only year of that figure in our verified data.1 The Q1 2026 cash balance is about twice that. That is our comparison, not a company statement, and it uses a 2023 spending level. It does suggest the company can fund research without needing outside money. Capital expenditure is recorded as exactly $48.7 million in both fiscal 2024 and fiscal 2025.1 The two figures are identical, which is unusual enough that we flag it as stated and do not read anything into it.
What that cash is funding
On October 26, 2026, Incyte presented new results at the ESMO Congress for its KRAS G12D inhibitor INCB161734 in pancreatic and colorectal cancer. It also presented results for a bispecific antibody, INCA338901, in colorectal cancer.3 In pancreatic cancer, Phase 1 data (cut-off July 6, 2026; 54 patients) covered INCB161734 at 1,200 mg once daily. It was combined with gemcitabine/nab-paclitaxel in 26 patients or mFOLFIRINOX in 27 patients. The company described efficacy as encouraging and safety as favorable.3 Early-phase data from a company's own presentation is not proof of a marketable drug. Incyte also announced collaborations with BMS and Synnovation to test the drug alongside two other agents.3 Partnering suggests it wants to spread the cost and risk of these combinations.
Revenue anchors elsewhere in the sector
Few of the companies in this wave of news have Incyte's cash flow, but some have recurring income. BioArctic's royalty on Eisai's Alzheimer's drug Leqembi was SEK 179 million in Q2 2026, up about 10% from Q2 2025.4 That understates the underlying trend. Q2 2025 included a one-time stockpiling effect in China of around JPY 5.3 billion. Excluding it, BioArctic says royalty revenues grew approximately 43% year-over-year.4 The company's own words: "Excluding the stockpiling effect, royalty revenues in Q2 2026 grew approximately 43 percent compared to the same quarter last year."4 Total Leqembi sales were JPY 29.3 billion in the quarter.4 Note that the 43% is the royalty holder's own adjusted figure, and 10% is the unadjusted one.
The pre-revenue majority
Vor Biopharma reported final 104-week results from its Phase 3 TELIGAN trial in IgA nephropathy, a kidney disease. The annualized kidney-function decline (eGFR slope) was -0.6 versus -5.7 mL/min/1.73 m² per year on placebo, a difference of 5.1 with p<0.001.2 The company reported 89% and 81% reductions in the risk of confirmed 30% and 40% declines in kidney function.2 That is a strong clinical result. Our dossier contains no revenue or cash data for Vor, so we cannot say what it is worth or how it will be funded.
Others are earlier still, and their timelines are company statements. Ernexa said it remained on schedule to file its IND (the application to begin human trials) for ERNA-101 in the third quarter of 2026, with a first-in-human Phase 1 trial in the fourth quarter.5 Prelude expected an IND for PRT13722 by mid-2026 and a Phase 1 start in ER-positive breast cancer in the second half of 2026.6 Our dossier does not confirm that either filing happened, and both dates have now passed or are passing. Akari's CEO frames patients whose cancers no longer respond to antibody-drug conjugates as "a significant, growing unmet need". The company's planned Phase 1 is in mid-2027.7 For an investor, a mid-2027 first trial means any revenue is years away, and cash to get there is the central question.
People and a thin AI thread
Idorsia appointed Begoña Carreño-Gómez as Chief Business Development Officer, effective November 1, 2026.8 A dealmaking hire is consistent with the sector's focus on partnering, but the dossier gives no financial detail behind it. On AI-designed drugs, Radical Numerics says AI-designed viruses have treated its first patient, in an experimental treatment for drug-resistant E. coli.9 That is one patient and a company statement, with no efficacy data. It is a signal worth following, not a financial result.
How much to trust each source
Our measured reliability scores matter here. Of 6,322 claims checked from the NewsEOD press-release feed, 53% held up. That feed carried the Vor, BioArctic and Akari items.2,4,7 The Ernexa item came from a separate feed where 34% of 3,660 checked claims held up.5 Anti-ageing claims from the startup Generation Lab, which says its treatment "restores health and youth to multiple tissues", come through MIT Technology Review. Only 6% of 16 checked claims from that source held up.10 It is a company claim with no evidence in the dossier, and we do not treat it as established. Only the Incyte figures above are fidelity-checked against filings. The rest should be read as what companies say about themselves.
What to watch
Three things follow from the data. First, whether Incyte's 2025 profit and cash flow hold in 2026, which Q1 2026 cash of $3,461.1 million so far supports.1 Second, whether BioArctic's underlying royalty growth persists once the China stockpiling comparison drops out.4 Third, whether Ernexa and Prelude confirm their filings, and whether Akari's mid-2027 date holds.5,6,7
